Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1175 USD | -1.26% | +0.34% | +657.96% |
Mar. 04 | Sunshine Biopharma, Inc. announced that it expects to receive $0.01 million in funding | CI |
Jan. 30 | Sunshine Biopharma, Inc. Announces Executive Changes | CI |
Financials (USD)
Sales 2023 | 24.09M | Sales 2024 * | 44.4M | Capitalization | 6.02M |
---|---|---|---|---|---|
Net income 2023 | -4M | Net income 2024 * | 2M | EV / Sales 2023 | 0.29 x |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 0.14 x |
P/E ratio 2023 |
-1.43
x | P/E ratio 2024 * |
0.67
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 90.55% |
1 day | -1.26% |
Managers | Title | Age | Since |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Marc Beaudoin
COO | Chief Operating Officer | - | Jan. 24 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Natan
BRD | Director/Board Member | 71 | 22-01-31 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+2.95% | 212B | |
+0.74% | 209B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock Sunshine Biopharma, Inc.
- Stock SUNE BIOP - OTC Markets